Ensign Peak Advisors
ABUS icon

Ensign Peak Advisors’s Arbutus Biopharma ABUS Stock Holding History

Ensign Peak Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
27,000
-600
-2% -$2.63K ﹤0.01% 1546
2026
Q1 		$124K Hold
27,600
– – ﹤0.01% 1510
2025
Q4 		$133K Sell
27,600
-17,400
-39% -$78.2K ﹤0.01% 1477
2025
Q3 		$204K Hold
45,000
– – ﹤0.01% 1646
2025
Q2 		$139K Buy
45,000
+23,150
+106% +$76.9K ﹤0.01% 1690
2025
Q1 		$76.3K Buy
+21,850
New +$72.9K ﹤0.01% 1685

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors's ABUS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Arbutus Biopharma (ABUS) stake by 2.2% in Q2 2026, selling an estimated $2.63K and leaving 27,000 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1546.

Ensign Peak Advisors first reported a position in ABUS in Q1 2025 and has held it in 6 quarters since. The position peaked at $204K in Q3 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Ensign Peak Advisors held 27,000 shares of Arbutus Biopharma worth $130K as of Q2 2026.
  • Ensign Peak Advisors sold 600 Arbutus Biopharma shares in Q2 2026, an estimated $2.63K.
  • Arbutus Biopharma made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1546 holding.
  • Ensign Peak Advisors first reported a position in Arbutus Biopharma in Q1 2025 and has held it in 6 quarters since.
  • Ensign Peak Advisors's Arbutus Biopharma position peaked at $204K in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.